TY - JOUR
T1 - A Refined Population Pharmacokinetic Model-Based Guideline for Individualized PEGasparaginase Dosing in Pediatric Acute Lymphoblastic Leukemia
AU - Brigitha, Leiah J.
AU - Zaky, Karen
AU - Pieters, Rob
AU - Van Der Sluis, Inge M.
N1 - Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2025/4/1
Y1 - 2025/4/1
N2 - BACKGROUND: In the Dutch Childhood Oncology Group ALL11 protocol, PEGasparaginase dosing was individualized for standard-risk and medium-risk patients with acute lymphoblastic leukemia. After using our pragmatic old guideline, we aimed to improve individualized PEGasparaginase dosing by developing a population pharmacokinetic model-based dosing guideline.METHOD: After the 3 doses of 1500 IU/m 2 administered in induction, standard-risk patients received 1 individualized dose and medium-risk patients 14, targeting trough activity levels between 100 and 250 IU/L. The effectiveness, adherence, and toxicity of our new dosing guideline was assessed and compared with the old guideline.RESULTS: In total, 92 patients (714 samples) were included in the new dosing group and 509 patients (4539 samples) were included in the old dosing group. Comparing the effectiveness, we found that 32% (22/67) of patients in the new and 13% (47/354) of patients in the old dosing group were within the target range after the first individualized dose ( P < 0.001). Among medium-risk patients, a median of 3 dose reductions was needed to reach and maintain levels within the target range in the new dosing group compared with 5 in the old dosing group ( P < 0.001). With a continuous PEGasparaginase dosing schedule, target trough activity levels were reached after 2 dose reductions in the new group versus 4 in the old dosing group. The adherence to the new guideline was >99%, with 6/714 recommended doses deviating from the guideline. With exception of a lower proportion of patients with increased (≥grade 3) serum alanine transaminase (34% new vs 64% old, P < 0.05) in the new dosing group, toxicity was comparable between guidelines.CONCLUSIONS: With the new dosing guideline, fewer dose-reduction steps are necessary to reach and remain within the target. The high adherence rate emphasized its simplicity and practicality, confirming that it can be easily integrated into clinical practice.
AB - BACKGROUND: In the Dutch Childhood Oncology Group ALL11 protocol, PEGasparaginase dosing was individualized for standard-risk and medium-risk patients with acute lymphoblastic leukemia. After using our pragmatic old guideline, we aimed to improve individualized PEGasparaginase dosing by developing a population pharmacokinetic model-based dosing guideline.METHOD: After the 3 doses of 1500 IU/m 2 administered in induction, standard-risk patients received 1 individualized dose and medium-risk patients 14, targeting trough activity levels between 100 and 250 IU/L. The effectiveness, adherence, and toxicity of our new dosing guideline was assessed and compared with the old guideline.RESULTS: In total, 92 patients (714 samples) were included in the new dosing group and 509 patients (4539 samples) were included in the old dosing group. Comparing the effectiveness, we found that 32% (22/67) of patients in the new and 13% (47/354) of patients in the old dosing group were within the target range after the first individualized dose ( P < 0.001). Among medium-risk patients, a median of 3 dose reductions was needed to reach and maintain levels within the target range in the new dosing group compared with 5 in the old dosing group ( P < 0.001). With a continuous PEGasparaginase dosing schedule, target trough activity levels were reached after 2 dose reductions in the new group versus 4 in the old dosing group. The adherence to the new guideline was >99%, with 6/714 recommended doses deviating from the guideline. With exception of a lower proportion of patients with increased (≥grade 3) serum alanine transaminase (34% new vs 64% old, P < 0.05) in the new dosing group, toxicity was comparable between guidelines.CONCLUSIONS: With the new dosing guideline, fewer dose-reduction steps are necessary to reach and remain within the target. The high adherence rate emphasized its simplicity and practicality, confirming that it can be easily integrated into clinical practice.
KW - asparaginase TDM
KW - evidence-based dosing
KW - individual asparaginase dosing
KW - pediatric ALL
KW - PEGasparaginase
KW - Precision Medicine/methods
KW - Antineoplastic Agents/administration & dosage
KW - Humans
KW - Child, Preschool
KW - Infant
KW - Male
KW - Asparaginase/pharmacokinetics
KW - Dose-Response Relationship, Drug
KW - Models, Biological
KW - Adolescent
KW - Female
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
KW - Polyethylene Glycols/administration & dosage
KW - Child
UR - https://www.scopus.com/pages/publications/85201421825
UR - https://www.mendeley.com/catalogue/344e80c0-603a-3f40-b0c8-02fe5794a2af/
U2 - 10.1097/FTD.0000000000001252
DO - 10.1097/FTD.0000000000001252
M3 - Article
C2 - 39137448
AN - SCOPUS:85201421825
SN - 0163-4356
VL - 47
SP - 289
EP - 296
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
IS - 2
ER -